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Background: The predictive factors for treatment response in patients with severe chronic
obstructive pulmonary disease (COPD) are unknown. We investigated predictive factors for
response to fluticasone propionate/salmeterol (FSC) in severe COPD patients.
Methods: This prospective, open-label, non-comparative study included 921 adult patients
with severe COPD (baseline forced expiratory volume in 1 s (FEV1) <50% of predicted), a history
of repeated exacerbations, and symptoms despite bronchodilator treatment. FSC (500 mg/
50 mg) was delivered via an inhaler, twice a day, for 12 weeks. The primary efficacy endpoint
was the response rate for inspiratory capacity (IC), FEV1, or quality of life (QoL), assessed with
the Saint George’s respiratory questionnaire, at week 6 and week 12.
Results: The overall response rate to FSC at 6 and 12 weeks was 79%. The corresponding rates
for FEV1, IC, and QoL were 38%, 55%, and 62%, respectively. More than 40% of patients showed
a response for IC and/or QoL without being responders for FEV1. Overall lung function and QoL
were improved. FSC was well tolerated with a safety profile consistent with that observed
previously.I, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1,
fluticasone propionate/salmeterol combination; FVC, forced vital capacity; IC, inspiratory capacity;
t to treat; LABA, long acting beta2 agonist; PFT, pulmonary function tests; PIFR, peak inspiratory flow
l volume; SD, standard deviation; SGRQ, Saint George’s respiratory questionnaire; TLC, total lung
C, summary of the product characteristics.
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Predictive factors for evaluation of response to fluticasone propionate/salmeterol 251Conclusion: Nearly 80% of patients responded to FSC treatment in this real-life study. Improve-
ments in IC and QoL at 12 weeks revealed a clinically relevant response in patients with no
improvement in FEV1. IC reversibility to salbutamol before treatment might represent, better
than FEV1, a prognostic factor of response to FSC in severe COPD. Moreover these tests are
easy to perform routinely and in large numbers of patients.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by chronic airflow limitation which is not fully
reversible.1,2 The aim of treatment in patients with FEV1
(forced expiratory volume in 1 s) < 50% is to control
symptoms, particularly dyspnea, to reduce exacerbations,
to improve exercise tolerance, and to improve or at least
maintain lung function and health status.1e3 Dyspnea
observed at rest in patients with severe COPD is often
related to hyperinflation and reduction of inspiratory flow.4
Current guidelines recommend short-acting bronchodi-
lators such as beta2-adrenergic agonists as first-line therapy
and symptomatic treatment.1 Inhaled corticosteroids (ICS)
combined with long-acting beta2-agonists (LABAs) are rec-
ommended in more severe patients (FEV1 <50% and
repeated exacerbations). LABAs are useful for the
management of dyspnea5,6; they increase exercise capacity
by reducing dynamic hyperinflation,7,8 reduce rescue
medications,9,10 and improve health status.11 Salmeterol
(50 mg twice daily) is known to improve FEV1 and symp-
toms,12 inspiratory capacity (IC), and health status.1e3 The
involvement of airway inflammation in the pathophysiology
of COPD provides a rationale for the use of ICS,14,15 namely
by reducing neutrophils in the sputum. When used as
symptomatic treatment of COPD, fluticasone propionate
resulted in significant improvement in FEV1 and symp-
toms.16,17 Rate of exacerbation and decline in health status
were also both reduced.18,19
The mechanisms of action of LABAs such as salmeterol
and of corticosteroids such as fluticasone propionate are
complementary and could result in additive or synergistic
effects.20 Indeed, improvements are more pronounced
when a combination of LABA and ICS was used.21,22
Combination therapy is effective at reducing mechanical
abnormalities by decreasing lung hyperinflation.23,24 In
patients with FEV1 <50% treatment with a fluticasone
propionate/salmeterol (FSC) combination was more effec-
tive than salmeterol alone at reducing the rate of exacer-
bations.25 The aim of this study was to assess the effects of
FSC under real-life conditions in COPD patients with FEV1
<50%. Predictive factors for response to FSC in terms of
FEV1, IC, and QoL were investigated.
Methods and materials
Patients
Adult patients with a diagnosis of COPD confirmed by clin-
ical examination and pulmonary function tests (PFTs), with
baseline FEV1 <50% of predicted normal, were included. All
patients presented with symptoms despite bronchodilatortreatment and a history of repeated exacerbations defined
as “any acute respiratory episode with worsening of
symptoms that had resulted in treatment such as antibac-
terial, systemic corticosteroids, or nebulized bronchodi-
lator therapy”.
Exclusion criteria included: treatment with FSC within 3
months prior to inclusion, use of oral corticosteroids within
the previous 2 months, hypersensitivity to any of the FSC
components, known history of clinical symptoms or labo-
ratory findings of a serious uncontrolled disease * or any
medical condition that would place the patient at risk or
would interfere with the study evaluations. Pregnant or
lactating women or women of childbearing potential
without a reliable contraceptive method were also
excluded.
Approval for the study was obtained from the local
ethics committee. All patients gave their written informed
consent.
Study design
This multicenter, prospective, open-label, non-compara-
tive study (protocol n SFCF4021/SCO101717) was con-
ducted on an outpatient basis in 302 centers across France.
Patients were treated with fluticasone propionate/salme-
terol (500 mg/50 mg); Seretide 500/50; Diskus, adminis-
tered as a single inhalation twice daily for 12 weeks.
Clinical assessments were performed at inclusion, week 6
and week 12.
Pulmonary function tests (PFTs)
Patients were asked to refrain from using short-acting
bronchodilators for at least 6 h prior to testing. The usual
parameters (FEV1, forced vital capacity (FVC), FEV1/FVC %)
were measured. IC was determined by spirometry: patients
were asked to breathe regularly for at least four tidal
maneuver breaths until end-expiratory lung volume was
stable. They were then asked to take a deep breath to total
lung capacity (TLC) followed by a full expiration to residual
volume (RV).
Measurements of FEV1 and FVC were performed after IC
measurement according to ERS recommendations.25 At
inclusion, measurements were performed before and
20 min after 400 mg salbutamol inhalation
Dyspnea grading and use of rescue bronchodilators
Dyspnea was assessed using a visual analog scale (VAS) and
the CEE scale. The VAS is a horizontal 100-mm scale graded
from 0 mm (“no breathlessness”) to 100 mm (“asphyxia”).
The CEE scale is a fiveepoint scale comprising: stage 1:
dyspnea on strenuous exertion; stage 2: dyspnea at normal
pace on walking uphill; stage 3: dyspnea at normal pace on
level ground with someone else, need to stop or slow down
252 A.-B. Tonnel et al.notably; stage 4: dyspnea at own pace on level ground; and
stage 5: dyspnea on short exertion (dressing, shaving,
brushing hair). The use of rescue medication was also
recorded within 2 weeks preceding each visit.
Quality of life
QoL was assessed at baseline and at weeks 6 and 12 using
the Saint George’s Respiratory Questionnaire (SGRQ) in its
French version.26 This questionnaire is widely used in
COPD studies. As well as producing an overall score (total
score, from bestZ 0 to worstZ 100), it is also possible to
calculate scores for the individual domains of symptoms,
activity and impact (on daily life, i.e., social functioning,
psychological disturbances resulting from airway
disease).
COPD exacerbations
These were documented in the past 12 months and
prospectively during the study.
Safety evaluation
Safety of FSC was based on reporting of adverse events
(AEs).
Efficacy analysis
The primary efficacy endpoint was the proportion of
subjects with at least one of the following after 6 or 12
weeks of treatment: (i) reduction of four or more units in
SGRQ total score; (ii) increase in IC by 0.15 L or 10% from
baseline (bronchodilator pre-dose value); (iii) increase in
FEV1 by 0.20 L or 10% of predicted value.
Secondary efficacy endpoints included: (i) PFT; (ii)
dyspnea assessed by the patient using the VAS; (iii)
frequency of rescue bronchodilator use; (iv) QoL assessed
with the SGRQ; and (v) COPD exacerbations.
Statistical analysis
Based on the assessment of predictive value of IC revers-
ibility on response to FSC treatment (5% one-sided signifi-
cance level; 90% power; 80% probability estimate of
response after 6 or 12 weeks of treatment; estimated
OR Z 1.3 for patients with baseline IC reversibility one
standard deviation below mean IC reversibility), 1000
patients were required.
The proportion of responders is described with 95%
confidence intervals (CI). The profile of responders was
studied by univariate logistic analysis including the
following parameters as covariates: age, gender, body mass
index (BMI), smoking status, time since COPD diagnosis,
number of COPD exacerbations in the past 12 months, IC
reversibility, % predicted FEV1, FEV1 reversibility, peak
inspiratory flow rate (PIFR), % predicted FVC, FEV1/FVC,
short-acting bronchodilator use, dyspnea, QoL scores,
previous COPD treatments, concomitant cardiovascular
disease. Multivariate analysis was then performed using
a stepwise method including all covariates with a prog-
nostic value at a 10%-level of significance in univariate
analysis. Analysis was performed globally (response in atleast one of the three criteria) and for each criterion
separately, in order to determine whether the predictive
factors for response were similar irrespective of the
response criterion chosen.
Changes in IC, FEV1 (L and % predicted), FVC (L and %
predicted), PIFR (L/min) and SGRQ scores from baseline
were described at weeks 6 and 12 as means  95%CI. Mean
change in dyspnea score and number of days/week of
bronchodilator use were also described at weeks 6 and 12.
The rate of COPD exacerbations on treatment was
described. Time to first exacerbation was studied using
censored data analysis. The probability of not exacerbating
was estimated using the KaplaneMeier method.
Primary efficacy analysis was conducted on the intent to
treat (ITT) population, defined as all patients who had
received at least one dose of study medication and with
available data for assessment of at least one efficacy
endpoint. AEs were analyzed in the safety population,
defined as all patients who had received at least one dose
of study medication.
Results
A total of 928 patients were recruited in the study: 922
were included in the safety analysis and 921 in the ITT
population. In the ITT population, 106 patients (12%) were
withdrawn from the study due to onset of an AE (n Z 48,
5%), lack of efficacy (n Z 10, 1%), COPD exacerbation
(n Z 3, <1%), consent withdrawal (n Z 18, 2%), lost to
follow-up (nZ 9, 1%), or other reason (nZ 18, 2%). Forty-
five patients (5%) had major protocol violations, usually
FEV1 50% predicted.
Patient characteristics at baseline
Table 1 shows the main characteristics of the ITT pop-
ulation. Treatment with LABA or ICS at inclusion was
reported by 40% and 42% of patients respectively, and 26%
received a bronchodilator/ICS combination. At least one
cardiac pathology was reported in 45% of the patients. The
mean (SD) number of COPD exacerbations in the previous
year was 2.5  1.4. 18% of patients were hospitalized at
least once for COPD, and 50% received systemic cortico-
steroids. Dyspnea on the CEE scale was mostly stage 2 (33%)
or 3 (37%); 26% of patients had a higher stage (4 or 5). On
the VAS scale, the mean dyspnea score was 55.2  19.4. At
inclusion, mean (SD) FEV1 was 1.09  0.30 L and
38.7  8.5% predicted, while mean IC was 1.91  0.66 L.
Mean total SGRQ score was 53.3  17. 88% of patients
required short-acting bronchodilators as rescue medication
for an average of 4.23  2.99 days/week.
After 12 weeks, average IC increased by 0.108 L and
10.7% of the baseline value, FEV1 by 0.135 L and 4.8% of the
predicted normal, and FVC by 0.151 L and 4.2% of the
predicted normal (Table 2). QoL improved after 12 weeks of
treatment by at least 6 points in all SGRQ scores, as shown
in Table 3. At week 12, 392/789 (50%) patients experienced
an improvement in dyspnea, 34% no change, and 16%
impairment. Requirement for short-acting bronchodilators
decreased, with a mean change of 1.6  3.2 days/week.
Among the 921 patients, 213 (23%) experienced at least one
Table 1 Demographic and baseline characteristics of the
patients (ITT population, N Z 921).
Characteristic N (%)
Sex (M/F, % male) 774/147 (84)
Age (years), mean  SD 65.1  9.9
Smoking status
Current smoker 273 (30)
Former smoker 599 (65)
Never smoked 49 (5)
Duration of COPD
<1 year 114 (12)
1e5 years 274 (30)
5e10 years 236 (26)
10e15 years 156 (17)
15 years 139 (15)
COPD exacerbations in the past 12 months
0 29 (3)
1 155 (17)
2 337 (37)
3 231 (25)
>3 167 (18)
Short-acting bronchodilator use (in the past 2 weeks)
0e1 day/week 259 (28)
2e3 days/week 116 (13)
4e5 days/week 85 (9)
6e7 days/week 459 (50)
Dyspnea stage (CEE scale)
1 37 (4)
2 303 (33)
3 345 (37)
4 166 (18)
5 70 (8)
Dyspnea VAS (mean  SD) 55.2  19.4
ITT: intent to treat; COPD: chronic obstructive pulmonary
disease; VAS: visual analog scale.
Table 2 Evolution of lung function parameters in the ITT popu
Parameter Baseline value
N (mean  SD)
ICa (L) (% change) 813 1.91  0.66
FEV1
a(L) 917 1.09  0.30
FEV1 (% predicted) 917 38.7  8.5
FVC a(L) 916 2.17  0.66
FVC (% predicted) 916 60.4  14.9
ITT: intent to treat; CI: confidence interval; IC: inspiratory capacity;
a Before bronchodilator.
Predictive factors for evaluation of response to fluticasone propionate/salmeterol 253on-treatment COPD exacerbation; 2% of patients were
hospitalized.
Proportion of responders to treatment
A total of 686/869 subjects (78.9%, 95%CI: 76.1e81.5)
responded to FSC according to one or more of the three
criteria. The proportion of responders was: 54.7% [95%CI:
51.1e58.2] for IC, 38.0% [95%CI: 34.8e41.3%], for FEV1, and
61.7% [95%CI: 58.3e65.0] for QoL.
Among the 686 responders, 287 (42%) responded to one of
the three criteria, 249 (36%) to two, and 150 (22%) to all three
criteria. Among the 287 responders to only one criterion, 88
(31%) were IC-based responders, 41 (14%) FEV1-based
responders, and 158 (55%) QoL-based responders. Among the
249 responders to two criteria, 59 (24%) were IC and FEV1-
based responders, 114 (46%) IC and QoL-based responders,
and 76 (31%) FEV1 and QoL-based responders (Fig. 1).
Profile of responders
PFTs at inclusion were similar between responders and non-
responders, except for IC and FEV1 reversibility to salbu-
tamol. Mean baseline IC reversibility was 11.0  29.0% in
responders compared to 3.0  37.8% in non-responders.
Baseline IC reversibility to salbutamol was a predictive
factor for treatment response. IC reversibility was 10% in
43% (221/517) of responders and 31% (41/134) of non-
responders. FEV1 reversibility was 10% in 14% (92/666) of
responders and 9% (15/175) of non-responders. The changes
from baseline in responders and non-responders are
summarized in Tables 4 and 5 for lung function parameters
and SGRQ scores, respectively.
The following factors were predictive of treatment
response by univariate analysis: time since COPD diagnosis,
previous ICS, previous long-term oxygen therapy, dyspnea,
IC reversibility to salbutamol, FEV1 reversibility to salbu-
tamol, and SGRQ score. In multivariate analysis (Table 6), 3lation (N Z 921).
Change from baseline
Visit N Mean [95%CI]
week 6 730 0.09 [0.05; 0.13]
10.2 [7.4; 13.1]
week 12 688 0.11 [0.07; 0.15]
10.7 [8.0; 13.4]
week 6 852 0.13 [0.11; 0.15]
week 12 798 0.14 [0.11; 0.16]
week 6 852 4.50 [3.83; 5.17]
week 12 798 4.77 [4.05; 5.48]
week 6 849 0.14 [0.11; 0.17]
week 12 796 0.15 [0.12; 0.18]
week 6 849 4.02 [3.15; 4.88]
week 12 796 4.19 [3.26; 5.12]
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity.
Table 3 Evolution of SGRQ scores from baseline (ITT population, N Z 921).
SGRQ score Baseline Change from baseline week 12
N Mean  SD N Mean [95%CI]
Total 883 53.3  17.7 733 7.0 [8.1; 5.9]
Symptoms 887 63.8  20.0 727 6.9 [8.2; 5.7]
Activity 875 65.7  18.5 710 6.0 [7.3; 4.7]
Impact 887 43.0  20.8 737 7.5 [8.8; 6.2]
SGRQ: St George’s respiratory questionnaire; ITT: intent to treat; CI: confidence interval.
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ibility to salbutamol (reversibility 10%; OR Z 1.78),
absence of previous long-term oxygen therapy (ORZ 2.22),
mild dyspnea (OR Z 1.81).
In multivariate analysis, the probability of being an IC-
based responder (Table 7) was associated with IC revers-
ibility 10% to salbutamol at inclusion. The probability of
being an FEV1-based responder was associated with FEV1
reversibility to salbutamol, and IC reversibility 10% to
salbutamol (Table 8). The probability of being a QoL-based
responder was associated with FEV1 reversibility to salbu-
tamol (Table 9).
Influence of ICS or LABA treatment at baseline
In univariate analysis, patients already treated with ICS at
inclusion had a lower probability of global response
(OR Z 0.67 [95%CI: 0.46e0.96]), QoL-response (OR Z 0.69
[95%CI: 0.51e0.94]) and FEV1-response (OR Z 0.54 [95%CI:
0.40e0.72]). This was also the case for patients treated
with LABAs at inclusion: OR Z 0.87 [95%CI: 0.62e1.21],
0.78 [95%CI: 0.59e1.04] and 0.76 [95%CI: 057e1.01],Figure 1 Responders to each criterion (Venn diagram). A:
responders for IC criteria only-88. B: responders for FEV1
criteria only-41. C: responders for QoL criteria only-158. D:
responders for IC and FEV1-59. E: responders for FEV1 and QoL-
76. F: responders for IC and QoL-114. G: responders for all
three criteria-150.respectively. Thus, previous treatment with ICS or LABA
was not a predictive factor for IC-based response.
Safety
Median exposure to FSC was 85 days. A total of 251 AEs was
reported in 178 subjects (19%), with respiratory disorders
the most frequent (7%). Sixty-two subjects (7%) experi-
enced 89 AEs considered as drug-related. Respiratory
disorders, particularly hoarseness, dysphonia, dyspnea,
cough, and throat irritation were the most frequently
reported (3%). Drug-related AEs led to premature discon-
tinuation of FSC in 28 patients (3%). Serious AEs related to
the underlying disease were reported in 49 (5%) patients.
Seven patients died during the treatment period. There
were no serious drug-related AEs. Serious COPD exacerba-
tions were reported in 9 subjects (1%), but only one led to
treatment withdrawal.
Discussion
This study investigated the response to FSC in patients with
severe COPD (FEV1 <50% of predicted normal), repeated
exacerbations, and persistent symptoms. Nearly 80% of
patients responded to treatment according to the study
criteria which were chosen according to ATS/ERS recom-
mendations.2 There is increasing evidence that FEV1 should
not be the only parameter used to evaluate response to
treatment in COPD patients.27
It is known that changes in FEV1 failed to detect accu-
rately functional response to bronchodilators such as beta-2
agonists and anticholinergics.28,29 Calverley studied 660
COPD patients coming from the ISOLDE Study and responding
to ERS diagnostic criteria. Spirometric parameters, espe-
cially FEV1, were performed on 3 successive occasions,
before and after bronchodilator challenge (salbutamol, tio-
tropium and combination of both).30 Results clearly demon-
strated that inmoderate or severe COPD, the bronchodilator
responsiveness do not allow to discriminate COPD patients in
“responders” or “non responders”. In fact, bronchodilator
responsiveness is a continuous variable and is unable to
classify COPD patients and to predict long-term improve-
ment after treatment.31 Tashkin32 reported similar findings
with tiotropium. With this drug, efficacy of treatment was
independent of the presence or absence of a short term
response on the first day of treatment. Moreover, pharma-
cological characteristics of tiotropium also explain that
a single dose is unable to predict long-term effects.32
Another work, also derived from a post-hoc analysis of
Table 4 Lung function parameters in treatment responders and non-responders.
Parameter Baseline value Change from baseline at week 12
N (Mean  SD) N Mean [95%CI]
ICa (L) R 616 1.89  0.67 567 0.20 [0.15; 0.25]
NR 154 1.99  0.58 121 0.32 [0.39; 0.26]
FEV1
a(L) R 686 1.10  0.31 649 0.18[0.16; 0.20]
NR 180 1.06  0.26 149 0.06 [0.09; 0.03]
FEV1 (% predicted) R 686 39.0  8.5 649 6.31 [5.51; 7.12]
NR 180 38.3  8.5 149 1.97 [2.90; 1.04]
FVC a(L) R 686 2.16  0.66 649 0.22 [0.19; 0.26]
NR 179 2.19  0.66 147 0.16 [0.23; 0.10]
FVC (% predicted) R 686 60.1  14.7 649 6.17 [5.16; 7.18]
NR 179 61.7  15.2 147 4.54 [6.36; 2.72]
CI: confidence interval; IC: inspiratory capacity; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; R: responder; NR:
noneresponder.
a Before bronchodilator.
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14 days) in patients with COPD. Again, there was no rela-
tionship between the change in FEV1 after prednisolone
testing and the response to inhaled beta-2 agonist.
All these data are justifying development of additional
functional parameters such as the inspiratory capacity (IC).
COPD patients, particularly those with severe disease,
suffer from dyspnea related to lung hyperinflation resulting
in restrictions on ventilatory capacity and reduced exercise
tolerance. IC correlates closely with symptoms such as
dyspnea.34,35 Significant reductions in lung hyperinflation
have been observed in patients with severe COPD that did
not respond in terms of FEV1. The ratio of IC to TLC as
a measure of lung hyperinflation has been reported as an
independent risk factor for mortality in COPD patients.36
Measurement of the effect of treatment on dynamic
hyperinflation is therefore required and can be reliably
evaluated by IC.37,38 Nevertheless it is sure that as for
FEV1, the variability or conversely the stability of IC
measurements should be studied throughout the follow-up
of patients.Table 5 Evolution of SGRQ scores from baseline in treatment r
SGRQ score Baseline
N Mean 
Total R 664 53.5  1
NR 172 51.2  1
Symptoms R 666 64.6  2
NR 173 60.9  1
Activity R 658 65.5  1
NR 172 64.1  1
Impact R 667 43.1  2
NR 173 40.8  2
SGRQ: St George’s respiratory questionnaire; CI: confidence interval;As COPD is a complex disease, with multiple manifes-
tations, measurement of health status is also a part of COPD
evaluation.39 Other parameters such as SGRQ, BMI or
dyspnea have been identified as prognostic markers of
treatment response in studies on pulmonary
rehabilitation.40e42
Based on these considerations, response to FSC was
evaluated using concomitantly three parameters (IC, FEV1,
and QoL), and potential predictive factors were analyzed in
a univariate model. As patients without significant FEV1
reversibility to salbutamol could exhibit a clinically signifi-
cant increase in IC, reversibility of IC to salbutamol at
inclusion was investigated as a potential predictive factor
of response. The significance of a response in FEV1 and QoL
was determined according to thresholds validated previ-
ously.1,29,43 For IC, a threshold of 10% was considered
significant based on available data; this threshold was
confirmed subsequently.44
The design of our study has to be discussed: the main
purpose was to identify predictive factors of response to
FSC treatment. A double-blind study was not carried out inesponders and non-responders.
Change from baseline week 12
SD N Mean [95%CI]
7.6 603 9.7 [10.9; 8.5]
7.7 130 5.7 [4.2; 7.2]
0.2 598 8.4 [9.9; 7.0]
9.3 129 0.1 [2.4; 2.6]
8.4 583 8.4 [9.9; 7.0]
8.3 127 5.2 [3.3; 7.1]
0.6 605 10.7 [12.1; 9.2]
1.0 132 6.9 [4.8; 9.1]
R: responder; NR: non-responder.
Table 6 Profile of treatment responders (ITT population,
N Z 921).
Effect - multivariate
analysis
Odds ratios [95%CI] p
IC reversibility (10% vs.
<10%)
1.78 [1.16; 2.74] 0.008
Long-term oxygen
therapy (Yes vs. No)
0.45 [0.26; 0.79] 0.005
Dyspnea (CEE stages 3e5
vs. CEE stages 1e2)
0.55 [0.34; 0.89] 0.014
Time since COPD
diagnosis (1-year
increment)
0.97 [0.94; 0.99] 0.003
SGRQ symptoms score
(4-unit increment)
1.06 [1.02; 1.10] 0.007
ITT: intent to treat; CI: confidence interval; IC: inspiratory
capacity; COPD: chronic obstructive pulmonary disease; SGRQ:
St George’s respiratory questionnaire.
Table 8 Profile of FEV1-based responders (ITT population,
N Z 921).
Effect Odds ratios [95%CI] p
FEV1 reversibility (10% vs.
<10%)
3.37 [1.97; 5.75] <0.001
Long-term oxygen therapy
(Yes vs. No)
0.49 [0.26; 0.92] 0.026
Dyspnea (CEE stages 3e5 vs.
CEE stages 1e2)
0.58 [0.40; 0.84] 0.004
Inhaled corticosteroids
(Yes vs. No)
0.60 [0.41; 0.87] 0.007
BMI
(<18.5 or 30.0 kg/m2 vs.
18.5–<25.0 kg/m2)
1.79 [1.13; 2.86] 0.037
(25.0–<30.0 kg/m2 vs.
18.5–<25.0 kg/m2)
1.40 [0.93; 2.12]
IC reversibility (10% vs.
<10%)
1.45 [1.01; 2.08] 0.046
% predicted FVC
(10-percent increment)
0.83 [0.73; 0.94] 0.004
Age (1-year increment) 0.98 [0.96; 1.00] 0.020
Time since COPD diagnosis
(1-year increment)
0.98 [0.95; 1.00] 0.086
ITT: intent to treat; CI: confidence interval; FEV1: forced
expiratory volume in 1 s; BMI: body mass index; IC: inspiratory
capacity; FVC: forced vital capacity; COPD: chronic obstructive
pulmonary disease.
Table 9 Profile of QoL-based responders (ITT population,
N Z 921).
256 A.-B. Tonnel et al.order to stay close to a real-life situation (follow-up of
patients unchanged, known treatment, etc). Results
obtained in randomized COPD studies, which can change
the usual course of treatment, often differ from those
obtained in cohort studies (e.g. rate of exacerbations).13
Furthermore, previous studies comparing FSC to flutica-
sone propionate or salmeterol alone have demonstrated
better results with combination therapy in terms of FEV1, IC
and QoL.20,24,45e47 The characteristics of the patients at
inclusion were consistent with those expected in severe
COPD in terms of mean FEV1 at inclusion, exacerbations,
and symptoms despite bronchodilator use. IC values were
generally lower than the reference values established by
Tantucci in a control population.44 The improvement in lung
function parameters was comparable to that obtained
previously with FSC.45,47 After 12 weeks of treatment, IC
was increased by 0.108 L on average, which corresponds to
a 10.2% improvement in the baseline value, FEV1 by 0.135 L
and 4.8% of predicted normal, and FVC by 0.151 L and 4.2%
of predicted normal. An increase in IC was also observed in
other studies after bronchodilator use,23,24,48 and was
greater in patients with expiratory flow limitation, and in
those with decreased baseline IC.49 The present study alsoTable 7 Profile of IC-based responders (ITT population,
N Z 921).
Effect - multivariate
analysis
Odds ratios [95%CI] p
IC reversibility (10% vs.
<10%)
3.24 [2.30; 4.57] <0.001
% predicted FVC (10-
percent increment)
0.84 [0.75; 0.94] 0.002
Time since COPD
diagnosis (1-year
increment)
0.97 [0.95; 0.99] 0.014
IC: inspiratory capacity; ITT: intent to treat; CI: confidence
interval; FVC: forced vital capacity; COPD: chronic obstructive
pulmonary disease.confirmed in clinical practice that FSC not only improved
airflow obstruction but provided clinical benefits in terms
of QoL.20
Evaluation of the 3 criteria showed the following data:
only 22% of patients were responders to all three criteria,
48% were FEV1 responders, and 60% IC responders. Thus,
many responders obtained by the way of IC improvement
would have been missed if only FEV1 was used. Moreover, in
multivariate analysis, IC reversibility to salbutamol at
inclusion was predictive of the global response to treat-
ment and of response based on IC (OR Z 3.24) or FEV1Effect Odds ratios [95%CI] p
Long-term oxygen
therapy (Yes vs. No)
0.38 [0.23; 0.61] <0.001
FEV1 reversibility (10%
vs. <10%)
1.65 [1.00; 2.72] 0.051
Time since COPD
diagnosis (1-year
increment)
0.96 [0.94; 0.98] <0.001
SGRQ total score (4-unit
increment)
1.09 [1.04; 1.14] <0.001
SGRQ symptoms score
(4-unit increment)
1.04 [1.00; 1.08] 0.063
QoL: quality of life; ITT: intent to treat; CI: confidence interval;
FEV1: forced expiratory volume in 1 s; COPD: chronic obstruc-
tive pulmonary disease; SGRQ: St George’s respiratory
questionnaire.
Predictive factors for evaluation of response to fluticasone propionate/salmeterol 257(OR Z 1.45) while FEV1 reversibility was only predictive of
response based on FEV1 or QoL, but not based on IC.
Thus, this study confirms that FEV1 is not sufficient to
test response to treatment and that FEV1 reversibility to
400 mg salbutamol at inclusion is poorly predictive of
treatment response. Measuring IC reversibility may be more
helpful. Although IC is not yet spread, IC can be measured
routinely in clinical practice, as demonstrated by the high
number of correct values obtained in our trial. However, we
need additional data to define the value of IC improvement
after bronchodilator testing and to clearly distinguish
“responders” from “non responders”.
Eighteen percent of patients were only responders using
QoL criteria and did not show clinically significant
improvement using functional criteria. There was a strong
link between clinical improvement and QoL: QoL improved
dramatically in responders but deteriorated in non-
responders but results confirm the latest recommendations
of ATS/ERS on the importance of investigating all outcomes
to evaluate treatment response. As reported previously,
QoL measurement is more appropriate for evaluating large
groups of patients rather than at the individual level.50
In conclusion, this real-life study shows that nearly 80% of
patients with severe COPD, frequent exacerbations, and
symptoms despite bronchodilator use respond to FSC. A 3
month therapeutic test seems useful to evaluate the treat-
ment effect. Over 40% of patients were IC and/or QoL
responders but not FEV1 responders, confirming that FEV1
should not be the only parameter used to measure treatment
efficacy in COPD. So IC reversibility to salbutamol before
treatment and monitoring IC on treatment seems a better
predictive tool than FEV1 and might help the clinician define
the most appropriate therapy for severe COPD.Conflict of interest statement
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